PP 008
Alternative Names: PP-008Latest Information Update: 11 Jan 2023
At a glance
- Originator Primary Peptides
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Facioscapulohumeral muscular dystrophy; Inclusion body myositis
- Discontinued Pancreatic cancer
Most Recent Events
- 10 Jan 2023 Discontinued - Preclinical for Pancreatic cancer in Canada (Parenteral) as of Janaury 2023 (Primary Peptides pipeline, January 2023)
- 10 Jan 2023 Early research in Facioscapulohumeral muscular dystrophy in Canada (unspecified route) as of Janaury 2023 (Primary Peptides pipeline, January 2023)
- 10 Jan 2023 Early research in Inclusion body myositis in Canada (unspecified route) as of Janaury 2023 (Primary Peptides pipeline, January 2023)